Skip to main content

Table 2 Indexes of β-cell function, insulin resistance and insulin sensitivity by treatment group over the three time points of the trial. Values are mean (standard deviation) for normally distributed variables and median (Q1-Q3) for skewed variables. PI(0−7) and PI(7−10) are P values for interaction between treatment allocation and time of visit in the repeated measures ANOVA model, for the pairwise comparisons between 0 and seven months and seven and ten months respectively, corrected for multiple testing by Bonferroni method. PI overall is P for interaction between treatment allocation and time of visit in the whole ANOVA model

From: Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia

 

Baseline

7 months

 

10 months

  
 

Empagliflozin

Placebo

Empagliflozin

Placebo

PI(0−7)

Empagliflozin

Placebo

PI(7−10)

PI overall

Indexes of β-cell function

 

Insulinogenic index

84.8 (58.8, 100.0)

72.4 (48.0, 111.7)

64.2 (57.1, 98.3)

57.9 (48.8, 75.2)

0.47

107.3 (78.3, 129.4)

65.1 (47.8, 88.3)

0.33

0.69

First phase Stumvoll

800.2 (600.0)

921.8 (596.0)

897.1 (460.9)

795.1 (617.3)

0.55

1066.0 (525.5)

844.0 (503.9)

0.55

0.55

 s phase Stumvoll

242.0 (130.7)

265.5 (137.0)

253.5 (104.0)

237.4 (140.9)

0.47

297.3 (121.9)

248.9 (117.8)

0.47

0.47

 C-peptide index

2.82 (2.40, 3.39)

2.85 (2.03, 3.44)

2.58 (2.09, 3.69)

2.56 (1.90, 3.64)

0.33

2.69 (2.10, 3.79)

2.98 (2.02, 3.44)

0.33

0.40

totAUCIGI

45.5 (23.3)

51.1 (24.6)

39.2 (15.2)

42.3 (19.8)

0.18

51.9 (19.7)

43.3 (21.11)

0.67

0.18

HOMA2-β (mU/l, mmol/l)

72.6 (61.9, 94.2)

73.5 (58.6, 101.8)

70.5 (50.5, 117.0)

76.5 (47.5, 123.5)

0.55

83.5 (60.0, 92.4)

88.4 (54.2, 104.2)

0.55

0.55

Proinsulin/Insulin

0.18 (0.07)

0.17 (0.06)

0.17 (0.07)

0.16 (0.06)

0.71

-

-

-

0.71

Indexes of insulin resistance

 

HOMA-IR (traditional)

4.0 (1.8)

4.3 (3.0)

2.6 (1.3)

4.0 (2.5)

0.07

4.0 (2.8)

4.5 (3.2)

0.011

0.19

HOMA2-IR

1.5 (1.1, 1.8)

1.5 (1.0, 2.1)

1.4 (0.6, 1.7)

1.4 (0.9, 2.3)

0.28

1.5 (1.0, 1.8)

1.6 (1.0, 2.1)

0.03

0.20

VAI

1.39 (1.09, 1.63)

1.64 (1.16, 2.44)

1.08 (0.82, 1.82)

1.63 (1.15, 2.02)

0.82

1.12 (0.77, 1.90)

1.45 (1.30, 2.22)

0.82

0.82

LAP

37.2 (26.9, 51.4)

46.8 (32.7, 62.7)

36.1 (19.4, 48.0)

42.1 (30.2, 54.0)

0.95

33.84 (28.5, 50.4)

44.1 (35.3, 59.3)

0.95

0.95

Indexes of insulin sensitivity

 

QUICKI

0.32 (0.3, 0.33)

0.32 (0.30, 0.34)

0.33 (0.32, 0.36)

0.32 (0.30, 0.33)

0.0001

0.32 (0.31, 0.34)

0.31 (0.30, 0.33)

0.004

0.01

HOMA2-S

66.8 (54.6, 88.3)

68.5 (47.7, 101.3)

71.1 (59.0, 171.3)

70.5 (44.3, 108.5)

0.001

68.9 (56.9, 96.8)

64.6 (47.1, 99.0)

0.014

0.03

Stumvoll MCR120

9.26 (8.43, 9.67)

9.14 (8.27, 9.61)

9.68 (8.46, 10.04)

9.06 (8.22, 9.55)

0.0001

9.22 (8.46, 10.04)

9.06 (8.22, 9–55)

0.004

0.003

Matsuda Index

2.22 (1.48–3.15)

2.53 (1.59–3.02)

2.78 (2.29–4.36)

3.13 (2.13–3.59)

0.14

2.32 (1.82–2.51)

3.04 (1.02–4.00)

0.34

0.05

  1. AUCIGI: area under the curve of insulinogenic index; HOMA-IR: homeostatic model assessment for insulin resistance; ISI: insulin sensitivity index; LAP: lipid accumulation product; MCR: Metabolic clearance rate of glucose; QUICKI: quantitative insulin sensitivity check index; VAI: visceral adiposity index.